Cargando…

Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic inflammatory disorder where incidence and severity of myocardial infarction are increased. Data on the incidence and outcome of stroke are conflicting. Thus, we investigated outcome after Ischemia/Reperfusion (I/R) brain injury in a mouse model of RA and assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonetti, N. R., Diaz-Cañestro, C., Liberale, L., Crucet, M., Akhmedov, A., Merlini, M., Reiner, M. F., Gobbato, S., Stivala, S., Kollias, G., Ruschitzka, F., Lüscher, T. F., Beer, J. H., Camici, G. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379411/ https://www.ncbi.nlm.nih.gov/pubmed/30778120 http://dx.doi.org/10.1038/s41598-019-38670-z

Ejemplares similares

TNF‐α antagonism rescues the effect of ageing on stroke: Perspectives for targeting inflamm‐ageing
por: Liberale, Luca, et al.
Publicado: (2021)

Glycoprotein Ib clustering in platelets can be inhibited by α-linolenic acid as revealed by cryo-electron tomography
por: Stivala, Simona, et al.
Publicado: (2020)

Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
por: Stivala, Simona, et al.
Publicado: (2017)

Lifelong dietary omega-3 fatty acid suppresses thrombotic potential through gut microbiota alteration in aged mice
por: Saeedi Saravi, Seyed Soheil, et al.
Publicado: (2021)

Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor
por: Liberale, Luca, et al.
Publicado: (2019)

Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults
por: Filipovic, Mark G., et al.
Publicado: (2018)

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
por: Wijbrandts, C A, et al.
Publicado: (2008)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis
por: Perry, M G, et al.
Publicado: (2009)

Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring
por: Smeele, Hieronymus T W, et al.
Publicado: (2022)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling
por: Pullerits, Rille, et al.
Publicado: (2008)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Effects of acute administration of trimethylamine N-oxide on endothelial function: a translational study
por: Jomard, Anne, et al.
Publicado: (2022)

Sirtuin 1 in Endothelial Dysfunction and Cardiovascular Aging
por: Ministrini, Stefano, et al.
Publicado: (2021)

Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
por: Ernestam, Sofia, et al.
Publicado: (2006)

Tumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity
por: Zaghlol, Heba M., et al.
Publicado: (2019)

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
por: Low, Audrey S L, et al.
Publicado: (2017)

Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
por: Stavropoulos-Kalinoglou, Antonios, et al.
Publicado: (2012)

Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2004)

Rheumatoid arthritis and coronary atherosclerosis: two cousins engaging in a dangerous liaison
por: Klingenberg, Roland, et al.
Publicado: (2015)

Alternatively Spliced Tissue Factor Is Not Sufficient for Embryonic Development
por: Sluka, Susanna H. M., et al.
Publicado: (2014)

Dual Role of Endothelial Nitric Oxide Synthase in Oxidized LDL-Induced, p66(Shc)-Mediated Oxidative Stress in Cultured Human Endothelial Cells
por: Shi, Yi, et al.
Publicado: (2014)

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
por: Wijbrandts, C A, et al.
Publicado: (2008)

Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis
por: Cacciapaglia, Fabio, et al.
Publicado: (2016)

Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis
por: Giollo, Alessandro, et al.
Publicado: (2021)

Therapeutic inhibition of tumour necrosis factor alpha reduces oligoclonality in the selected T-cell receptor BV families in rheumatoid arthritis
por: Pierer, M, et al.
Publicado: (2003)

Protective role of membrane tumour necrosis factor in the host’s resistance to mycobacterial infection
por: Allie, Nasiema, et al.
Publicado: (2008)

Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome
por: Coenen, Marieke J. H., et al.
Publicado: (2010)

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
por: van Kuijk, A W R, et al.
Publicado: (2009)

Microarray analysis for molecular characterization of disease activity and measuring outcomes of anti-tumour necrosis factor therapy in rheumatoid arthritis
por: Stuhlmüller, B, et al.
Publicado: (2005)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis
por: Klaasen, R., et al.
Publicado: (2012)

Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor
por: Souto-Carneiro, M Margarida, et al.
Publicado: (2009)

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
por: Strand, Vibeke, et al.
Publicado: (2017)

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
por: Fröde, Tânia Silvia, et al.
Publicado: (2002)

Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, Hubert, et al.
Publicado: (2005)

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
por: Ochi, Sae, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cv3jtm261aqjmoh8jhfqktt3vc